JULÄINE™, a unique PLLA-based collagen biostimulator
Based on advanced regenerative biomaterial design, JULÄINE™ is a unique poly-L-lactic acid (PLLA) based, next-generation collagen biostimulator that empowers the body to activate its own collagen production, delivering natural-looking facial rejuvenation and long-lasting aesthetic results.
The science about Lactic Acid is evolving. Lactic Acid is no longer seen as an inert byproduct of glycolysis, but has been recognized as a multifunctional signalling molecule that has the potential to regenerate collagen and delay the signs of aging.
Designed by the LASYNPRO™ - Lactic Acid Induced Synthesis of Collagen Protein - microsphere technology, JULÄINE™ is easy to inject, integrates smoothly into the skin, and demonstrates a strong safety profile.
Aesthetic trends are changing. People are increasingly looking for treatment options that provide natural-looking rejuvenation and protect facial harmony and individual identity. Developed with the evolving expectations of today’s aesthetics patients in mind, JULÄINE™ supports healthcare practitioners in achieving outcomes that are refined and enduring.
Powered by a collagen-activating technology and developed in collaboration with experts across multiple specialties, JULÄINE™ represents a unique regenerative biomaterial technology in modern medical aesthetics.
See what makes JULÄINE™ stand outAt Nordberg Medical, a strong evidence-based approach to product development is the key to meet high standards in terms of efficacy and safety of our solutions. Our research teams are highly focussed on providing scientific data that support JULÄINE™’s safety profile, its clinical efficacy and its regenerative potential in aesthetic medicine.
JULÄINE™ is CE-marked for use in Europe and manufactured according to high-quality production standards, ensuring safety and reliability for both patients and professionals.
JULÄINE™ is authorized for marketing in Europe and manufactured under stringent quality standards. Regulatory processes for additional markets, including the U.S., are currently underway. Production adheres to ISO 13485:2016, the global quality standard for medical devices.
Preclinical data support the biocompatibility and biodegradability of JULÄINE™’s poly-L-lactic acid microspheres.
Developed and manufactured in Sweden, JULÄINE™ ensures full product traceability and consistent production quality. Each batch undergoes strict quality control procedures to support product reliability.